Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination lipid-lowering therapy in diabetes.

Michael H Davidson1

  • 1Chicago Center for Clinical Research, Rush-Presbyterian-St. Luke's Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA. mdavidson@protocare.com

Current Diabetes Reports
|May 24, 2003
PubMed
Summary

Diabetic patients often need combination lipid therapy to reach cholesterol goals. Careful drug selection, avoiding high-dose statins with gemfibrozil, can reduce myopathy risk for safer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obicetrapib safety analysis: Pooled phase 3 clinical trial experience.

American journal of preventive cardiology·2026
Same author

Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.

American journal of preventive cardiology·2026
Same author

Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.

European heart journal·2026
Same author

The emerging role of CETP inhibition in the prevention of Alzheimer's disease.

American journal of preventive cardiology·2026
Same author

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026
Same author

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Patients with diabetes mellitus have stringent lipid targets: low-density lipoprotein (LDL) < 100 mg/dL and non-high-density lipoprotein (HDL) < 130 mg/dL, per NCEP ATP III guidelines.
  • Diabetic patients frequently require combination lipid-lowering therapy due to comorbidities and renal impairment, increasing the risk of statin-induced myopathy.
  • High-dose statins combined with fibrates, particularly gemfibrozil, significantly elevate the risk of myopathy in this population.

Purpose of the Study:

  • To evaluate safer combination lipid-lowering strategies for diabetic patients.
  • To identify therapeutic regimens that minimize the risk of myopathy while achieving lipid goals.

Main Methods:

  • Analysis of lipid-lowering therapy combinations in diabetic patients.
  • Focus on avoiding high-dose statins with specific fibrates (gemfibrozil).
  • Assessment of alternative combinations like fenofibrate or niacin with moderate-dose statins, and ezetimibe with statins.

Main Results:

  • Combining fenofibrate or niacin (if glucose control is adequate) with statins (≤ 40 mg) may reduce myopathy risk.
  • Ezetimibe offers a safe adjunctive therapy to statins for achieving LDL goals in diabetic patients.
  • Avoiding high-dose statins with gemfibrozil is crucial for improving safety.

Conclusions:

  • Combination lipid therapy in diabetics necessitates careful drug selection to balance efficacy and safety.
  • Fenofibrate, niacin, and ezetimibe represent safer alternatives or additions to statin therapy compared to gemfibrozil combinations.
  • Tailoring lipid-lowering regimens can significantly mitigate the risk of myopathy in diabetic patients.

Related Experiment Videos